Vincristine-induced neuropathy in the rat is not modified by drug-drug interactions with the P-glycoprotein inhibitor verapamil

Chemotherapy

Volumn 54, Issue 5, 2008, Pages 336-342

  Balayssac, David ^a,b,c,e   Cayre, Anne ^b,d   Ling, Bing ^a,b   Maublant, Jean ^b   Penault Llorca, Frederique ^b   Eschalier, Alain ^b,c   Coudore, François ^a,b,c   Authier, Nicolas ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d Institut Universitaire de Technologie en Genie Biologique   (France)

^e INSERM   (France)

Author keywords

99mTc sestamibi; Drug drug interactions; Neuropathy; P glycoprotein; Verapamil; Vincristine

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; Q 0750; QUINIDINE; UNCLASSIFIED DRUG; V 4629; VERAPAMIL; VINCRISTINE; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; MALE; NEUROPATHY; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SPINAL CORD; SPINAL GANGLION; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; DRUG INTERACTIONS; MALE; NERVOUS SYSTEM DISEASES; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL; VINCRISTINE;

EID: 49549085499     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151540     Document Type: Article

References (29)

1. Blower P, de Wit R, Goodin S, Aapro M: Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005;55:117-142.
2. Beijnen JH, Schellens JH: Drug interactions in oncology. Lancet Oncol 2004;5:489-496.
3. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
4. Balayssac D, Authier N, Cayre A, Coudore F: Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319-329.
5. Saito T, Zhang ZJ, Ohtsubo T, Noda I, Shibamori Y, Yamamoto T, Saito H: Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol 2001;121:735-742.
6. Saito T, Zhang ZJ, Tokuriki M, Shibamori Y, Yamamoto T, Noda I, Ohtsubo T, Saito H: Doxorubicin ototoxicity is induced in mice by combination treatment with cyclosporin A. Acta Otolaryngol 2001;121:787-793.
7. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-2524.
8. van Tellingen O, Buckle T, Jonker JW, van der Valk MA, Beijnen JH: P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer 2003;89:1776-1782.
9. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
10. Balayssac D, Cayre A, Authier N, Ling B, Maublant J, Eschalier A, Penault-Llorca F, Coudore F: Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. Eur J Pharmacol 2006;544:49-57.
11. Balayssac D, Cayre A, Authier N, Bourdu S, Penault-Llorca F, Gillet JP, Maublant J, Eschalier A, Coudore F: Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. J Peripher Nerv Syst 2005;10:301-310.
12. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984.
13. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F: A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 2003;24:797-805.
14. Randall LO, Selitto JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-419.
15. NeckerR, Bellon RF: Noxious thermal input from the rat tail: modulation by descending inhibitory influences. Pain 1978;4:231-242.
16. Grubbs F: Procedures for detecting outlying observations in samples. Technometrics 1969;11:1-21.
17. Meijer DKF, Lennernäs H: EUFEPS Conference on Drug Transporters at Copenhagen: integrative approaches in ADME research. Eur J Pharm Sci 2005;26:130-143.
18. Adenot M, Perriere N, Scherrmann JM, Lahana R: Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs. Chemotherapy 2007;53:70-72.
19. Bochner F, Somogyi AA, Chen ZR: Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites. Xenobiotica 1994;24:543-552.
20. Wang YH, Jones DR, Hall SD: Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 2005;33:664-671.
21. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304.
22. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD: Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006;34:1317-1327.
23. Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003;10:159-165.
24. Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M: Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy 2003;49:8-16.
25. 2+ channel blockers. Eur J Pharmacol 1992;217:137-141.
26. Sathiapalan RK, El-Solh H: Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 2001;18:543-546.
27. Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C: Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005;27:389-392.
28. Taylor CW, Dalton WS, Mosley K, Dorr RT, Salmon SE: Combination chemotherapy with cyclophosphamide, vincristine, Adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res Treat 1997;42:7-14.
29. Milroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer 1993;68:813-818.